Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'".
Levinstein MR, De Oliveira PA, Casajuana-Martin N, Quiroz C, Budinich RC, Rais R, Rea W, Ventriglia EN, Llopart N, Casadó-Anguera V, Moreno E, Walther D, Glatfelter GC, Weinshenker D, Zarate CA Jr, Casadó V, Baumann MH, Pardo L, Ferré S, Michaelides M.
Levinstein MR, et al. Among authors: baumann mh.
Mol Psychiatry. 2024 Dec 6. doi: 10.1038/s41380-024-02864-3. Online ahead of print.
Mol Psychiatry. 2024.
PMID: 39639176
No abstract available.